Preservation of ischemic myocardial tissue with an antagonist of vasoconstrictor eicosanoids
- 1 December 1984
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 62 (12) , 1487-1491
- https://doi.org/10.1139/y84-246
Abstract
A new antagonist of the vasoconstrictor eicosanoids, L-640,035, was studied in a standardized model of myocardial ischemia (MI) in anesthetized cats. This eicosanoid antagonist was not found to exert any overt hemodynamic action in cats subjected to a sham myocardial ischemia protocol. However, the antagonist markedly reduced the S-T segment of the electrocardiogram when administered 30 min after permanent occlusion of the left coronary artery. Moreover, circulating activities of the marker enzyme creatine kinase (CK) were markedly attenuated by L-640,035 3–5 h after the onset of MI. This was verified by cardiac biopsies 5 h post-MI since myocardial CK activities decreased much less in treated MI cats than in MI cats receiving only the vehicle for L-640,035 (i.e., ethanol). The active metabolite of the antagonist in biological fluids (i.e., L-636,499) markedly antagonized the vasoconstrictor actions of endoperoxide and thromboxane analogs, but not of noneicosanoids in isolated perfused coronary arteries.This publication has 2 references indexed in Scilit:
- INHIBITION OF PROSTANOID-MEDIATED PLATELET-AGGREGATION INVIVO AND INVITRO BY "3-HYDROXYMETHYL-DIBENZO(B,F)THIEPIN 5,5-DIOXIDE (L-640,035)1984
- Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2.Proceedings of the National Academy of Sciences, 1980